Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Positive 54.0%

Neg 0% Neu 0% Pos 54%

Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $60.